P

Pfizer

Makes cancer drugs, vaccines and other medicines

Lead Investigator

Full-TimeUpdated on 10/23/2026Deadline 11/4/26
$99.2k - $165.4k/yr
Mid
Bachelor's, Master's, PhD, Associate's
McPherson, KS, USA
In PersonOn-premise work; some possible travel.
Biology & BiotechBioprocess & Biomanufacturing
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree with at least 4 years of experience, a master's degree with at least 2 years of experience, a PhD with 0 or more years of experience, an associate's degree with 8 years of experience, or a high school diploma or equivalent with 10 years of relevant experience.
  • Demonstrated expertise in applying statistical methodologies to enhance manufacturing processes and quality control test methods.
  • Proficiency in the Microsoft Office Suite, including Word, Excel, PowerPoint, SharePoint, and Visio.
  • Exceptional verbal and written communication skills.
  • Strong presentation abilities.
  • Must be authorized to be employed in the United States by any employer; permanent work authorization in the United States is required.
Responsibilities
  • Lead or co-lead moderately complex projects, effectively managing time and resources.
  • Apply skills and knowledge to contribute to departmental work and resolve moderately complex problems.
  • Make decisions guided by policies in non-standard situations and operate independently in ambiguous scenarios.
  • Work independently on assignments, seek guidance on complex issues, and review own and others' work.
  • Use judgment and experience to become a resource for others and mentor colleagues.
  • Troubleshoot and resolve on-site issues, collaborating with site operations to ensure continuous audit readiness.
  • Identify high-risk areas, implement improvements, and interface with engineering and technical operations to enhance processes.
  • Manage changes in the area, guide operational teams, prepare resource forecasts, and identify improvement opportunities.
  • Facilitate agreements between teams, lead clinical production efforts, and ensure timely, injury-free, and defect-free execution.
  • Develop Operations Specialists' skills, review area Change Controls, strengthen compliance culture, and enforce safety regulations while sustaining lean management practices.
Desired Qualifications
  • Experience in a Good Manufacturing Practice (GMP) environment.
  • Previous management experience.
  • Strong problem-solving skills.
  • Ability to work collaboratively in a team environment.
  • Experience using common artificial intelligence tools, including generative technologies such as ChatGPT or Microsoft Copilot, to support problem solving and enhance productivity; curiosity about how these tools can improve outcomes and understanding of responsible artificial intelligence practices, including risk management and ethical use.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.